Compounds that modulate intracellular calcium
View Patent ↗Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.
1. A method for treating an autoimmune disease, heteroimmune disease or condition, or inflammatory disease in a mammal comprising administering to the mammal a compound having the structure of Formula (I):
wherein:
A is phenyl or benzofuranyl, wherein phenyl and benzofuranyl are each optionally substituted with at least one R; or A is phenyl substituted with two R groups on adjacent carbon atoms wherein the two R groups and the carbon atoms to which they are attached form a C 4 -C 8 cycloalkyl or C 3 -C 8 heterocycloalkyl;
R is selected from F, Cl, Br, I, —CN, —NO 2 , —CF 3 , —OH, —OR 3 , —OCF 3 , —C≡CH, —C≡CR 3 , C 1 -C 6 alkylenealkynyl, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 heteroalkyl, C 1 -C 6 haloalkyl, tetrazolyl, C 2 -C 6 heterocycloalkyl, phenyl, —NHS(═O) 2 R 3 , S(═O) 2 N(R 4 ) 2 , —C(═O)CF 3 , —C(═O)NHS(═O) 2 R 3 , —S(═O) 2 NHC(═O)R 4 , N(R 4 ) 2 , —N(R 4 )C(═O)R 3 , —CO 2 R 4 , —C(═O)R 3 , —OC(═O)R 3 , —C(═O)N(R 4 ) 2 , —SR 3 , —S(═O)R 3 , and —S(═O) 2 R 3 ;
J is a bond;
R 1 is CO 2 R 2 , wherein R 2 is hydrogen;
Z is O;
X is optionally substituted with at least one R;
B is selected from thiophene, pyrrole, pyridine, oxazole, thiazole, imidazole, thiadiazole, isoxazole, isothiazole, pyrazole, pyridazine, pyrimidine, pyrazine, oxadiazole, thiadiazole, triazole, indole, benzoxazole, benzothiazole, benzimidazole, benzoxadiazole, benzothiadiazole, benzotriazole, pyrazolopyridine, imidazopyridine, pyrrolopyridine, pyrrolopyrimidine, indolizine, purine, furopyridine, thienopyridine, furopyrrole, furofuran, thienofuran, 1,4-dihydropyrrolopyrrole, thienopyrrole, thienothiophene, quinoline, isoquinoline, furopyrazole, thienopyrazole, and 1,6-dihydropyrrolopyrazole;
each R 3 is independently selected from C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, phenyl, and benzyl;
R 4 is hydrogen; or
a pharmaceutically acceptable salt, solvate, N-oxide or prodrug thereof.
2. The method of claim 1 wherein the autoimmune disease is inflammatory bowel disease, rheumatoid arthritis, myasthenia gravis, multiple sclerosis, Sjogren's syndrome, type I diabetes, lupus erythematosus, psoriasis, osteoarthritis, scleroderma, and autoimmune hemolytic anemia.
3. The method of claim 1 wherein the heteroimmune disease or condition is graft-versus-host disease, graft rejection, atopic dermatitis, allergic conjunctivitis, organ transplant rejection, allogeneic or xenogenic transplantation, and allergic rhinitis.
4. The method of claim 1 wherein the inflammatory disease is uveitis, vasculitis, vaginitis, asthma, inflammatory muscle disease, dermatitis, interstitial cystitis, dermatomyositis, colitis, Crohn's disease, hepatitis, and chronic relapsing hepatitis.
5. The method of claim 1 wherein A is phenyl.
6. The method of claim 5 wherein phenyl is substituted with one R.
7. The method of claim 5 wherein phenyl is substituted with two R.
8. The method of claim 5 wherein phenyl is substituted with three R.
9. The method of claim 5 wherein R is selected from F, Cl, Br, I, or C 1 -C 6 alkyl.
10. The method of claim 1 wherein A is benzofuran.
11. The method of claim 10 wherein benzofuran is substituted with one R.
12. The method of claim 5 wherein X is B selected from benzoxazole, benzothiazole, benzimidazole, pyrazolopyridine, imidazopyridine, benzoxadiazole, benzothiadiazole, and benzotriazole wherein B is optionally substituted with at least one R.
13. The method of claim 12 wherein B is benzoxazole.
14. The method of claim 12 wherein B is benzothiazole.
15. The method of claim 12 wherein B is pyrazolopyridine.
16. The method of claim 12 wherein B is benzothiadiazole.
17. The method of claim 12 wherein R is selected from F, Cl, Br, I, —CN, —NO 2 , —CF 3 , —OH, —OR 3 , —OCF 3 , —C≡CH, —C≡CR 3 , C 1 -C 6 alkylenealkynyl, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 heteroalkyl, C 1 -C 6 haloalkyl, tetrazolyl, C 2 -C 6 heterocycloalkyl, and phenyl.
18. The method of claim 17 wherein R is selected from F, Cl, Br, and I.
19. The method of claim 1 wherein the compound is selected from:
20. The method of claim 1 wherein the compound of formula 1 has the structure
21. The method of claim 1 wherein the compound of formula 1 has the structure
22. The method of claim 1 wherein the compound of formula 1 has the structure
23. The method of claim 1 wherein the compound of formula 1 has the structure
24. The method of claim 1 wherein the compound of formula 1 has the structure